Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Chief Medical Officer | November 26, 2019 | December 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date November 26, 2019 · Filed December 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,067 |
Reported balance
After 2019-11-26 transaction · row 1
1 source rowRow 1 · 2019-11-26 · Exercise / conversion · Acquired 58,067 · Balance 58,067 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-09-01 | Direct | 91,135 |
Reported balance
After 2019-11-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-26 · Exercise / conversion · Disposed 58,067 · Balance 91,135 F1: On September 1, 2017 the Reporting Person was granted an option to purchase 149,202 shares of the Issuer's common stock, 25% of which vested on September 1, 2018 and the remainder of which vested or will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 1, 2017 the Reporting Person was granted an option to purchase 149,202 shares of the Issuer's common stock, 25% of which vested on September 1, 2018 and the remainder of which vested or will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2019 Filed Dec 19, 2019 21:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 58,067 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-19-074340 · a4.xml · derivative · entry 2 Kaufman Howard · CIK 0001744424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,135 Underlying: Common Stock · 58,067 shares Expires 2027-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On September 1, 2017 the Reporting Person was granted an option to purchase 149,202 shares of the Issuer's common stock, 25% of which vested on September 1, 2018 and the remainder of which vested or will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 26, 2019 Filed Dec 19, 2019 21:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 58,067 | $3.30 | $191,621.10 |
DisclosureSEC source: 0001104659-19-074340 · a4.xml · nonDerivative · entry 1 Kaufman Howard · CIK 0001744424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 80,500 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019723 · a4.xml · derivative · entry 1 Kaufman Howard · CIK 0001744424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,500 Underlying: Common Stock · 80,500 shares Expires 2029-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2020, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:24 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047455 · a4.xml · derivative · entry 1 Kaufman Howard · CIK 0001744424 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-07-19 F1 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.